DK3241561T3 - Konjugeret antistof eller bispecifik t-celle-engager, som selektivt binder enten tcr-beta konstant region 1 (trbc1) eller trbc2 - Google Patents

Konjugeret antistof eller bispecifik t-celle-engager, som selektivt binder enten tcr-beta konstant region 1 (trbc1) eller trbc2

Info

Publication number
DK3241561T3
DK3241561T3 DK17172755.5T DK17172755T DK3241561T3 DK 3241561 T3 DK3241561 T3 DK 3241561T3 DK 17172755 T DK17172755 T DK 17172755T DK 3241561 T3 DK3241561 T3 DK 3241561T3
Authority
DK
Denmark
Prior art keywords
trbc2
trbc1
tcr
bispecific
constant region
Prior art date
Application number
DK17172755.5T
Other languages
English (en)
Inventor
Martin Pulé
Paul Maciocia
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52649058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3241561(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB201403905A external-priority patent/GB201403905D0/en
Priority claimed from GB201416908A external-priority patent/GB201416908D0/en
Application filed by Autolus Ltd filed Critical Autolus Ltd
Application granted granted Critical
Publication of DK3241561T3 publication Critical patent/DK3241561T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK17172755.5T 2014-03-05 2015-03-05 Konjugeret antistof eller bispecifik t-celle-engager, som selektivt binder enten tcr-beta konstant region 1 (trbc1) eller trbc2 DK3241561T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201403905A GB201403905D0 (en) 2014-03-05 2014-03-05 Method
GB201416908A GB201416908D0 (en) 2014-09-25 2014-09-25 Method
EP15709319.6A EP3125934B1 (en) 2014-03-05 2015-03-05 Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region

Publications (1)

Publication Number Publication Date
DK3241561T3 true DK3241561T3 (da) 2025-06-30

Family

ID=52649058

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17172755.5T DK3241561T3 (da) 2014-03-05 2015-03-05 Konjugeret antistof eller bispecifik t-celle-engager, som selektivt binder enten tcr-beta konstant region 1 (trbc1) eller trbc2
DK15709319.6T DK3125934T3 (da) 2014-03-05 2015-03-05 Kimær antigenreceptor (car) med antigenbindende domæner over for den konstante region af t-cellereceptor beta

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15709319.6T DK3125934T3 (da) 2014-03-05 2015-03-05 Kimær antigenreceptor (car) med antigenbindende domæner over for den konstante region af t-cellereceptor beta

Country Status (24)

Country Link
US (2) US20170066827A1 (da)
EP (3) EP4610654A3 (da)
JP (5) JP6767872B2 (da)
KR (3) KR102235202B1 (da)
CN (4) CN112094347A (da)
AU (3) AU2015225944B2 (da)
BR (1) BR112016020304B1 (da)
CA (1) CA2940564C (da)
CL (4) CL2016002195A1 (da)
CU (1) CU24475B1 (da)
DK (2) DK3241561T3 (da)
ES (2) ES2758173T3 (da)
FI (1) FI3241561T3 (da)
HU (2) HUE047641T2 (da)
IL (3) IL278878B (da)
MX (3) MX2016010856A (da)
MY (1) MY173567A (da)
PE (2) PE20211887A1 (da)
PH (3) PH12016501646B1 (da)
PL (2) PL3241561T3 (da)
PT (2) PT3125934T (da)
RU (2) RU2744046C2 (da)
SG (3) SG10201906461SA (da)
WO (1) WO2015132598A1 (da)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230027993A1 (en) 2014-03-05 2023-01-26 Autolus Limited Methods
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
WO2016051205A1 (en) * 2014-10-03 2016-04-07 Isis Innovation Limited Analysis of t-cell monotypia
CA2937157A1 (en) * 2016-07-25 2018-01-25 Ucl Business Ltd Protein-based t-cell receptor knockdown
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
SG11201907299XA (en) 2017-02-08 2019-09-27 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
IL268755B2 (en) 2017-02-20 2025-12-01 Dragonfly Therapeutics Inc Proteins that bind her2, nkg2d, and cd16
AU2018247796A1 (en) * 2017-04-04 2019-08-29 F. Hoffmann-La Roche Ag Novel bispecific antigen binding molecules capable of specific binding to CD40 and to FAP
GB201709203D0 (en) * 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
AU2018322178A1 (en) * 2017-08-23 2020-02-20 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
WO2019129850A1 (en) * 2017-12-29 2019-07-04 Cellectis Off-the-shelf engineered cells for therapy
AU2018396083B2 (en) * 2017-12-29 2025-09-25 Cellectis Method for improving production of CAR T cells
GB201800298D0 (en) 2018-01-09 2018-02-21 Autolus Ltd Method
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3765054A4 (en) * 2018-01-19 2022-01-12 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR TARGETING GAMMA DELTA T LYMPHOCYTES USING CHIMERIC ANTIGEN RECEPTORS
EA202091887A1 (ru) 2018-02-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
US20210283180A1 (en) * 2018-07-06 2021-09-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Car t cell therapy to target t cell specific cancers
US20210277120A1 (en) * 2018-07-18 2021-09-09 The General Hospital Corporation Compositions and methods for treatment of t cell malignancies
GB201812650D0 (en) * 2018-08-03 2018-09-19 Autolus Ltd Molecular assessment of TRBC usage
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
GB201817172D0 (en) 2018-10-22 2018-12-05 Autolus Ltd Antibody
GB201817822D0 (en) 2018-10-31 2018-12-19 Autolus Ltd Binding domain
WO2020156335A1 (zh) * 2019-01-29 2020-08-06 上海交通大学 一种嵌合抗原受体及其应用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja) * 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
EP3927745A1 (en) * 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
CN110317266A (zh) * 2019-07-17 2019-10-11 东北农业大学 三种scFv抗体、其编码基因及其在制备治疗或预防O型口蹄疫病制剂中的应用
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
WO2021188454A1 (en) * 2020-03-16 2021-09-23 Marengo Therapeutics, Inc. Engineered cell compositions and methods of use thereof
GB202004263D0 (en) * 2020-03-24 2020-05-06 Autolus Ltd Antibody conjugate
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
WO2021205175A1 (en) 2020-04-09 2021-10-14 Autolus Limited Molecule
GB202101491D0 (en) 2021-02-03 2021-03-17 Autolus Ltd Molecule
GB2612450A (en) * 2020-04-24 2023-05-03 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
CN111537735A (zh) * 2020-05-15 2020-08-14 江西赛基生物技术有限公司 抗体检测试剂盒以及在免疫分析方面的应用
CN111549044B (zh) * 2020-07-13 2020-10-23 北京市肿瘤防治研究所 靶向trbc1 car-t细胞的制备方法与应用
US12173318B2 (en) 2020-08-18 2024-12-24 Medigene Immunotherapies Gmbh Enrichment of T cells using an anti-Cß antibody
KR20230074487A (ko) * 2020-08-26 2023-05-30 마렝고 테라퓨틱스, 인크. Trbc1 또는 trbc2를 검출하는 방법
EP4294841A1 (en) 2021-02-17 2023-12-27 The Johns Hopkins University Methods and materials for treating clonal t cell expansions
US20220267415A1 (en) * 2021-02-17 2022-08-25 The Board Of Regents Of The University Of Texas System Multimeric sars-cov-2 binding molecules and uses thereof
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
GB202112923D0 (en) * 2021-09-10 2021-10-27 Ucl Business Ltd Binding domain
EP4606385A1 (en) 2022-10-18 2025-08-27 Meiji Seika Pharma Co., Ltd. Therapeutic agent for t cell tumor
WO2024236163A1 (en) 2023-05-17 2024-11-21 Morphosys Ag T cell receptor beta constant region 2 (trbc2) antibodies
WO2024256824A1 (en) * 2023-06-14 2024-12-19 Autolus Limited Chimeric antigen receptors directed against trbc1 and trbc2
AU2024305993A1 (en) * 2023-06-28 2026-01-15 The Johns Hopkins University Trbc targeting antibody-drug conjugates
GB202310981D0 (en) 2023-07-18 2023-08-30 Autolus Ltd Method
WO2025051339A1 (en) * 2023-09-05 2025-03-13 Tiber Biotech Srl SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR
WO2025096673A1 (en) * 2023-10-30 2025-05-08 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising cells targeting cancer and methods of using the same
WO2025202622A1 (en) * 2024-03-26 2025-10-02 Oxford University Innovation Limited Antibodies
CN121299112B (zh) * 2024-09-12 2026-04-17 中国食品药品检定研究院 一种检测九型hpv疫苗或抗原原液体外相对效力的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69124518T2 (de) * 1990-08-09 1997-05-15 National Jewish Center For Immunology And Respiratory Medicine, Denver, Col. Herstellung monoklonaler Antikörper gegen menschliches Vbeta T-Zellrezeptorelement unter Verwendung rekombinanter DNA-Vektoren
US6790604B1 (en) * 1998-05-12 2004-09-14 Stefan A. Cohen Methods for identifying or diagnosing carcinoma cells with metastatic potential based on the measurement of lymphoid genes or their products in carcinoma cells
JP2006506954A (ja) * 2002-04-29 2006-03-02 ゲンパト７７ ファーマコジェネティクス エージー Ｔｃｒ及びｔｉｒｃ７に結合する新規な抗体、並びに治療及び診断におけるその使用
RU2355703C2 (ru) * 2002-10-09 2009-05-20 Медиджен Лимитед Одноцепочечные рекомбинантные т-клеточные рецепторы
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
US7741045B2 (en) * 2006-11-16 2010-06-22 General Electric Company Sequential analysis of biological samples
WO2009151628A2 (en) * 2008-06-12 2009-12-17 Gov't Of The Usa, As Represented By The Secretary, Department Of Health Human Services Monitoring tcr-b to determine hiv therapy and disease progression
AU2009288354A1 (en) * 2008-08-26 2010-03-11 Macrogenics Inc. T-cell receptor antibodies and methods of use thereof
CN102958942A (zh) 2009-12-29 2013-03-06 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
JP6000507B2 (ja) * 2010-09-30 2016-09-28 パナソニックヘルスケアホールディングス株式会社 診療情報登録装置
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
ES2719495T5 (en) 2012-05-07 2025-09-10 Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
KR102437522B1 (ko) * 2012-05-25 2022-08-26 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
US10443100B2 (en) * 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
CA2959428A1 (en) * 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
KR20260048600A (ko) * 2015-03-27 2026-04-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 변형된 t 세포 및 이의 제조 및 사용 방법

Also Published As

Publication number Publication date
CL2019001567A1 (es) 2019-08-16
KR20200027576A (ko) 2020-03-12
BR112016020304B1 (pt) 2024-02-27
RU2021101502A (ru) 2021-06-25
EP3241561B1 (en) 2025-04-30
EP3241561A1 (en) 2017-11-08
KR102088082B1 (ko) 2020-03-11
AU2019204925A1 (en) 2019-08-01
IL278879B1 (en) 2025-08-01
RU2744046C2 (ru) 2021-03-02
RU2016138421A (ru) 2018-04-05
CN118852462A (zh) 2024-10-29
AU2019204925B2 (en) 2021-02-18
EP4610654A2 (en) 2025-09-03
PT3125934T (pt) 2019-12-16
NZ723307A (en) 2021-06-25
JP7149304B2 (ja) 2022-10-06
ES3033286T3 (en) 2025-08-01
IL278879B2 (en) 2025-12-01
JP6767872B2 (ja) 2020-10-14
CL2019001568A1 (es) 2019-08-16
NZ761844A (en) 2021-06-25
KR102235201B1 (ko) 2021-04-05
MX2019013845A (es) 2020-02-24
EP4610654A3 (en) 2026-03-11
SG11201606583VA (en) 2016-09-29
AU2019204921A1 (en) 2019-08-01
PL3241561T3 (pl) 2025-09-01
NZ761848A (en) 2021-06-25
IL278879A (en) 2021-01-31
BR112016020304A2 (pt) 2017-10-17
MX2016010856A (es) 2017-04-13
JP2017510257A (ja) 2017-04-13
US20170334998A1 (en) 2017-11-23
DK3125934T3 (da) 2020-02-03
CL2018003096A1 (es) 2019-01-11
CN112094353A (zh) 2020-12-18
JP2017143838A (ja) 2017-08-24
KR102235202B1 (ko) 2021-04-05
WO2015132598A1 (en) 2015-09-11
EP3125934A1 (en) 2017-02-08
CA2940564A1 (en) 2015-09-11
ES2758173T3 (es) 2020-05-04
SG10201906461SA (en) 2019-09-27
CN112094347A (zh) 2020-12-18
SG10201906460PA (en) 2019-09-27
RU2018140694A (ru) 2018-12-10
CA2940564C (en) 2021-06-29
JP6767931B2 (ja) 2020-10-14
IL247110A0 (en) 2016-09-29
PE20170125A1 (es) 2017-03-16
CN106068276B (zh) 2020-09-18
IL278878A (en) 2021-01-31
PH12020550202B1 (en) 2023-11-15
KR20200027577A (ko) 2020-03-12
AU2019204921C1 (en) 2021-05-13
MX2019013846A (es) 2020-02-24
KR20160127130A (ko) 2016-11-02
PE20211887A1 (es) 2021-09-22
JP2024074907A (ja) 2024-05-31
AU2015225944A1 (en) 2016-09-01
CN106068276A (zh) 2016-11-02
AU2015225944B2 (en) 2019-07-11
EP3125934B1 (en) 2019-10-23
PL3125934T3 (pl) 2020-04-30
PH12016501646A1 (en) 2017-02-06
MY173567A (en) 2020-02-04
PH12020550202A1 (en) 2022-03-07
HUE047641T2 (hu) 2020-05-28
PT3241561T (pt) 2025-06-24
AU2019204921B2 (en) 2021-02-18
PH12020550203A1 (en) 2021-08-16
FI3241561T3 (fi) 2025-07-07
US20170066827A1 (en) 2017-03-09
CL2016002195A1 (es) 2017-05-19
RU2016138421A3 (da) 2018-07-25
IL278878B (en) 2022-07-01
JP2021184773A (ja) 2021-12-09
PH12016501646B1 (en) 2023-02-03
HUE071755T2 (hu) 2025-09-28
JP2020099356A (ja) 2020-07-02
CU24475B1 (es) 2020-03-04

Similar Documents

Publication Publication Date Title
DK3241561T3 (da) Konjugeret antistof eller bispecifik t-celle-engager, som selektivt binder enten tcr-beta konstant region 1 (trbc1) eller trbc2
IL269002A (en) Antibodies against pd-l1
IL255461A (en) Anti-transferrin receptor antibodies with tailored affinity
IL260151A (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a 02 complex
EP3315606C0 (en) ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
ZA201806356B (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
ZA201802451B (en) 2,4-dihydroxy-nicotinamides as apj agonists
BR112017024134A2 (pt) adaptação de taxa para agregação lte-wlan.
DK3795177T3 (da) Claudin-18.2-specifikke immunoreceptorer og t-celleepitoper
SG11201708061TA (en) Antibodies directed against interleukin 36 receptor (il-36r)
DK3169706T3 (da) Antistoffer, der binder axl
DK3515958T3 (da) Anisotrope kompositmaterialer baseret på polyisocyanater
EP3186225A4 (en) Cannabinoid type 1 receptor modulators
FR3025909B3 (fr) Audit de video sur le web
IL247773A0 (en) Pyridine-2-carboxamides 5,6-dimuters as cannabinoid receptor antagonists
DK3126486T3 (da) Immunassay, der benytter indfangningskonjugat
EP3897720A4 (en) BAFF-R BISPECIFIC T-LYMPHOCYTE ACTIVATING ANTIBODIES
IL247100A0 (en) Antibodies against cd84, preparations containing them and their uses
IL253920B (en) Antibodies targeting a galactan-based o-antigen of k. pneumoniae
LT3419598T (lt) Fosfomicino kompozicija, skirta parenteraliniam įvedimui
IL269731A (en) HASH stamp for multi-sequence files
HUE046915T2 (hu) Kv1.3 kálium csatorna antagonisták
FR3018175B1 (fr) Bi-structure maillee extensible, structures multicouches.
DK3649707T3 (da) Forstærkende, lettere multimodal fiber
FI20155650A7 (fi) Mekanismi vanttiruuvin lukitsemiseksi